Skip to main content
Clinical Trials/ISRCTN23032971
ISRCTN23032971CompletedNot Applicable

Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled study

Schering-Plough AS (Norway)0 sites663 target enrollmentStarted: February 1, 2005Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
663

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Patients 18 years or above with a minimum of two years history of SAR confirmed by either a positive skin prick test or a positive serologic allergen test to the relevant seasonal allergen
  • 2. Clinically symptomatic with SAR at baseline/inclusion with a minimum total nasal symptom score (rhinorrhoea, congestion, itching and sneezing) of at least 6 and rhinorrhoea being minimum 2 (moderate)
  • 3. Willingness to adhere to dosing and visit schedule
  • 4. Females of childbearing potential have to use medically accepted methods of birth control
  • 5. Written informed consent

Exclusion Criteria

  • 1. Pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitisation during the last 6 months
  • 2. Respiratory tract infection within the last two weeks
  • 3. Structural nasal abnormalities (including polyps)
  • 4. Use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group I corticosteroids allowed in only small areas), other antihistamines (oral or topical), any investigational drug during the last 30 days
  • 5. Pregnant or nursing females

Investigators

Sponsor
Schering-Plough AS (Norway)

Similar Trials